Paper Details

  1. Home
  2. Paper Details

Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.

Author: BadeschDavid, BenzaRaymond L, D'ElettoThomas A, FarberHarrison W, Gomberg-MaitlandMardi, HassounPaul M, HillNicholas S, PrestonIoana

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This review discusses the recent approval of macitentan, riociguat, and treprostinil as oral agents for pulmonary arterial hypertension (PAH), with riociguat being the first approved for chronic thromboembolic pulmonary hypertension (CTEPH). While these agents offer new therapeutic options, they also have potential drug interactions, adverse effects, dosing complexities, and costs. The review provides details on these aspects for each drug.
Paper Details　
Original Abstract of the Article :
In the past 18 months, the U.S. Food and Drug Administration approved macitentan, riociguat, and treprostinil as oral agents for the treatment of pulmonary arterial hypertension (PAH); riociguat also became the first agent approved for the treatment of chronic thromboembolic pulmonary hypertension (...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1513/AnnalsATS.201501-020AS

データ提供：米国国立医学図書館（NLM）

Oral Therapies for Pulmonary Hypertension: Navigating the Desert of Treatment Options

Pulmonary arterial hypertension (PAH) is a complex and often debilitating condition. Treating this condition involves navigating a landscape of diverse treatment options, each with its own set of challenges. This research offers insights into the latest oral therapies available for PAH, exploring their benefits and potential drawbacks.

The authors embark on a journey through the desert of PAH research, examining three recently approved oral agents: macitentan, riociguat, and treprostinil. They provide a comprehensive overview of these treatments, highlighting their efficacy, potential drug interactions, adverse effects, and dosing considerations.

A Oasis of Treatment Options: Weighing the Benefits and Risks

The research provides a valuable roadmap for clinicians, enabling them to choose the most suitable treatment for each patient. It emphasizes the importance of individualized care, considering factors such as potential drug interactions and the patient's overall health profile.

Navigating the Desert of Complexities: Finding a Path to Improved Outcomes

The study highlights the need for close collaboration between patients and clinicians. The complex nature of PAH requires a team approach, ensuring that each patient receives the best possible care.

Dr.Camel's Conclusion

This research sheds light on the evolving landscape of PAH treatment. It emphasizes the importance of staying informed about new therapies and their potential benefits and risks. As we continue to navigate the desert of medical research, we must embrace the complexities of patient care and work together to find the best possible solutions.

Date :
  1. Date Completed 2015-11-17
  2. Date Revised 2017-11-16
Further Info :

Pubmed ID

25590376

DOI: Digital Object Identifier

10.1513/AnnalsATS.201501-020AS

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.